Email Alert | RSS

北京大学学报（医学版） ›› 2020, Vol. 52 ›› Issue (2): 254-260. doi: 10.19723/j.issn.1671-167X.2020.02.010

• 论著 • 上一篇    下一篇

真实世界吡咯替尼治疗HER2阳性转移性乳腺癌的疗效及安全性

宋国红1,李惠平1,△(),邸立军1,严颖1,姜晗昉1,徐玲2,万冬桂3,李瑛4,王墨培5,肖宇5,张如艳1,冉然1,王环1   

  1. 1. 北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺肿瘤内科, 恶性肿瘤发病机制及转化研究教育部重点实验室, 北京 100142
    2. 北京大学第一医院乳腺疾病中心, 北京 100034
    3. 中日友好医院中西医结合肿瘤科, 北京 100029
    4. 中国人民解放军总医院肿瘤内科,北京 100853
    5. 北京大学第三医院肿瘤化疗与放射病科, 北京 100191
  • 收稿日期:2019-12-26 出版日期:2020-04-18 发布日期:2020-04-18
  • 通讯作者: 李惠平 E-mail:huipingli2012@hotmail.com

Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice

Guo-hong SONG1,Hui-ping LI1,△(),Li-jun DI1,Ying YAN1,Han-fang JIANG1,Ling XU2,Dong-gui WAN3,Ying LI4,Mo-pei WANG5,Yu XIAO5,Ru-yan ZHANG1,Ran RAN1,Huan WANG1   

  1. 1. Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education; Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China
    2. Breast Disease Center, Peking University First Hospital, Beijing 100034, China
    3. Department of TCM Oncology, China-Japan Friendship Hospital, Beijing 100029, China
    4. Department of Oncology, General Hospital of PLA, Beijing 100853, China
    5. Department of Tumor Chemotherapy and Radiation Sickness, Peking University Third Hospital, Beijing 100191, China
  • Received:2019-12-26 Online:2020-04-18 Published:2020-04-18
  • Contact: Hui-ping LI E-mail:huipingli2012@hotmail.com

RICH HTML

 22   

PDF (PC)

345

摘要：

目的 评价真实世界中口服吡咯替尼治疗表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)阳性转移性乳腺癌的疗效和毒副反应.方法: 回顾性分析72例接受以口服吡咯替尼为治疗基础的HER2阳性转移性乳腺癌患者.结果: 72例HER2阳性转移性乳腺癌患者中69例(95.8%)在复发转移阶段和/或(新)辅助治疗阶段曾行抗HER2靶向治疗;61例(84.7%)在复发转移阶段接受过抗HER2靶向治疗药物,包括曲妥珠单抗56例(77.8%),拉帕替尼36例(50.0%),T-DM1 4例(5.6%).72例患者中接受吡咯替尼联合化疗(±曲妥珠单抗)62例(86.1%),吡咯替尼联合内分泌治疗(±曲妥珠单抗)6例(8.3%),吡咯替尼(±曲妥珠单抗)4例(5.6%).72例患者均可评价疗效,其中完全缓解1例(1.4%),部分缓解18例(25.0%),疾病稳定41例(56.9%),疾病进展12例(16.7%).客观缓解率(完全缓解+部分缓解)为26.4%,中位无进展生存期(progression free survival, PFS)为7.6个月(95%CI: 5.5~9.7个月).36例曾接受过拉帕替尼治疗的患者中,吡咯替尼治疗的中位PFS为7.9个月(95%CI: 4.1~11.7个月), 15例脑转移患者中,吡咯替尼治疗的中位PFS为6.0个月(95%CI: 2.2~9.8个月).吡咯替尼相关的主要毒副反应为腹泻,共57例(79.2%),1~2级者48例(66.7%),3级者9例(12.5%).结论: 以吡咯替尼为基础的方案能够有效治疗HER2阳性转移性乳腺癌,包括拉帕替尼治疗失败及脑转移的患者,不良反应可耐受.

关键词: 吡咯替尼, 受体, 表皮生长因子, 乳腺肿瘤, 曲妥珠单抗, 拉帕替尼

Abstract:

Objective: Pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, showed promising antitumor activity and acceptable tolerability in phase Ⅱ and phase Ⅲ randomized clinical trials. We assessed the activity and safety of oral pyrotinib for human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer patients in the real world.Methods: We retrospectively analyzed 72 HER2 positive metastatic breast cancer (MBC) patients who received oral pyrotinib based regimens at Beijing Cancer Hospital and other four hospitals (Peking University First Hospital, China-Japan Friendship Hospital, General Hospital of PLA, Peking University Third Hospital) from August 2018 to September 2019. Progression free survival (PFS), objective response rate (ORR), adverse events (AE) of pyrotinib were investigated.Results: Seventy-two patients with HER2 positive MBC were enrolled. The median age of the patients was 55 years (range: 32-79 years). Sixty-nine (95.8%) patients had received anti-HER2 treatment in the metastatic and/or (neo) adjuvant settings; 61 (84.7%) patients had received anti-HER2 treatments in the metastatic setting in terms of trastuzumab 56 (77.8%) patients, lapatinib 36 (50.0%) patients, and T-DM1 4 (5.6%) patients. Among these 72 patients who received oral pyrotinib based regimens, 62 (86.1%) patients received pyrotinib (±trastuzumab) in combination with chemotherapy, 6 (8.3%) patients received pyrotinib (±trastuzumab) in combination with endocrine therapy and 4 (5.6%) patients received pyrotinib (±trastuzumab). Sixty-five (90.3%) patients received 400 mg pyrotinib once daily as initial dose, and 7 (9.7%) patients received 320 mg. Objectiveresponse and safety to pyrotinib based therapy were evaluable in all the 72 patients. One (1.4%) patient achieved complete response (CR), 18 (25.0%) patients achieved partial response (PR), 41 (56.9%) patients had stable disease (SD), and 12 (16.7%) patients had progressive disease (PD). The ORR (CR+PR) was 26.4% and the median PFS was 7.6 months (95%CI: 5.5-9.7 months). Among the 36 patients with prior lapatinib therapy, the median PFS was 7.9 months (95%CI: 4.1-11.7 months). Among the 15 patients with brain metastasis, the median PFS was 6.0 months (95%CI: 2.2-9.8 months). The main toxicities related to pyrotinib were diarrhea in 57 (79.2%) cases, and 48 (66.7%) cases with grade 1-2 as well as 9 (12.5%) cases with grade 3.Conclusion:Pyrotinib based therapy is an effective treatment for patients with HER2 positive MBC, including patients with lapatinib treatment failure and brain metastasis, and the toxicities can be tolerated.

Key words: Pyrotinib, Receptor, epidermal growth factor, Breast neoplasms, Trastuzumab, Lapatinib

中图分类号: 

  • R737.9

表1

72例患者基本人口学和疾病特征"

Items Data
Age
Median/years 55
Range/years 32-79
<65 years, n (%) 64 (88.9)
≥65 years, n (%) 8 (11.1)
Histologic type, n (%)
Invasive ductal 70 (97.2)
Others 2 (2.8)
Hormone receptor status, n (%)
Negative ER and PR 39 (54.2)
Positive ER and/or positive PR 33 (45.8)
Stage at first diagnosis of breast cancer, n (%)
Ⅰ-Ⅲ 59 (81.9)
Ⅳ 13 (18.1)
Sites of metastases, n (%)
Visceral 58 (80.6)
Liver 31 (43.1)
Lung 30 (41.7)
Brain 15 (20.8)
Nonvisceral 14 (19.4)
Previous anti-HER2 treatment, n (%)
Yes 69 (95.8)
(Neo) adjuvant setting* 31 (43.1)
Metastatic setting 61 (84.7)
No 3 (4.2)
Prior anti-HER2 therapy for metastases disease, n (%)
Trastuzumab 56 (77.8)
Lapatinib 36 (50.0)
T-DM1 4 (5.6)
No 11 (15.3)
Primary resistant to trastuzumab therapy, n (%)
Yes 26 (36.1)
No 46 (63.9)
Previous lines of chemotherapy in metastatic setting
Median, n 2
0, n (%) 7 (9.7)
1, n (%) 19 (26.4)
2, n (%) 11 (15.3)
≥3, n (%) 35 (48.6)

表2

近期疗效亚组分析"

Agents Total, n (%) Response, n (%) ORR, n (%) DCR, n (%)
CR PR SD PD
Total 72 (100.0) 1 (1.4) 18 (25.0) 41 (56.9) 12 (16.7) 19 (26.4) 60 (83.3)
Pyrotinib+chemotherapy (±trastuzumab)
Pyrotinib+capecitabine 40 (55.6) 1 (2.5) 13 (32.5) 20 (50.0) 6 (15.0) 14 (35.0) 34 (85.0)
Pyrotinib+vinorelbine (oral) 12 (16.7) 0 (0) 0 (0) 9 (75.0) 3 (25.0) 0 (0) 9 (75.0)
Pyrotinib+etoposide (oral) 4 (5.6) 0 (0) 1 (25.0) 2 (50.0) 1 (25.0) 1 (25.0) 3 (75.0)
Pyrotinib+gemcitabine 2 (2.8) 0 (0) 0 (0) 2 (100.0) 0 (0) 0 (0) 2 (100.0)
Pyrotinib+paclitaxel 1 (1.4) 0 (0) 0 (0) 1 (100.0) 0 (0) 0 (0) 1 (100.0)
Pyrotinib+albumin-bound paclitaxel 1 (1.4) 0 (0) 0 (0) 1 (100.0) 0 (0) 0 (0) 1 (100.0)
Pyrotinib+trastuzumab+gemcitabine 1 (1.4) 0 (0) 1 (100.0) 0 (0) 0 (0) 1 (100.0) 1 (100.0)
Pyrotinib+trastuzumab+albumin-bound paclitaxel 1 (1.4) 0 (0) 0 (0) 0 (0) 1 (100.0) 0 (0) 0 (0)
Pyrotinib+endocrine therapy (±trastuzumab)
Pyrotinib+endocrine therapy 3 (4.2) 0 (0) 1 (33.3) 2 (66.7) 0 (0) 1 (33.3) 3 (100.0)
Pyrotinib+trastuzumab+endocrine therapy 3 (4.2) 0 (0) 2 (66.7) 1 (33.3) 0 (0) 2 (66.7) 3 (100.0)
Pyrotinib (±trastuzumab)
Pyrotinib alone 3 (4.2) 0 (0) 0 (0) 2 (66.7) 1 (33.3) 0 (0) 2 (66.7)
Pyrotinib+trastuzumab 1 (1.4) 0 (0) 0 (0) 1 (100.0) 0 (0) 0 (0) 1 (100.0)

图1

72例患者无进展生存期"

图2

36例曾接受过拉帕替尼治疗患者的无进展生存期"

图3

15例脑转移患者的无进展生存期"

表3

72例患者治疗相关不良反应"

Toxicity All grades, n (%) Grade, n (%)
1 2 3 4
Diarrhea 57 (79.2) 26 (36.1) 22 (30.6) 9 (12.5) 0 (0)
Neutropenia 16 (22.2) 11 (15.3) 4 (5.6) 1 (1.4) 0 (0)
Anemia 9 (12.5) 4 (5.6) 5 (6.9) 0 (0) 0 (0)
Thrombocytopenia 2 (2.8) 0 (0) 2 (2.8) 0 (0) 0 (0)
Hand-foot syndrome 5 (6.9) 2 (2.8) 0 (0) 3 (4.2) 0 (0)
Rash 2 (2.8) 0 (0) 2 (2.8) 0 (0) 0 (0)
Fatigue 2 (2.8) 1 (1.4) 1 (1.4) 0 (0) 0 (0)
Increased ALT/AST 6 (8.3) 5 (6.9) 1 (1.4) 0 (0) 0 (0)
Increased TBIL 7 (9.7) 7 (9.7) 0 (0) 0 (0) 0 (0)

表4

72例患者吡咯替尼的剂量调整"

Starting dose Total, n (%) Dose adjustments
400 mg 65 (90.3) Reduction to 320 mg (n=11)
Reduction to 240 mg (n=2)
Reduction to 160 mg (n=1)
320 mg 7 (9.7) Increase to 400 mg (n=1)
Reduction to 160 mg (n=1)
[1] Slamon DJ, Clark GM, Wong SG , et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. Science, 1987,235(4785):177-182.
[2] Xu B, Hu X, Zheng H , et al. Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo) adjuvant trastuzumab: A prospective multicenter study[J]. Oncotarget, 2016,7(31):50643-50655.
[3] Cobleigh M, Yardley D, Brufsky AM , et al. Baseline characteristics, treatment patterns, and outcomes in patients with HER2-positive metastatic breast cancer by hormone receptor status from SystHERs[J]. Clin Cancer Res, 2020,26(5):1105-1113.
[4] Ma F, Li Q, Chen S , et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer[J]. J Clin Oncol, 2017,35(27):3105-3112.
[5] Li Q, Guan X, Chen S , et al. Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: a phase Ⅰ clinical trial[J]. Clin Cancer Res, 2019,25(17):5212-5220.
[6] Ma F, Ouyang Q, Li W , et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase Ⅱ study[J]. J Clin Oncol, 2019,37(29):2610-2619.
[7] Jiang ZF, Yan M, Hu XC , et al. Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase Ⅲ study[J]. J Clin Oncol, 2019,37(15 suppl):1001.
[8] Wong H, Leung R, Kwong A , et al. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2 + metastatic breast cancer [J]. Oncologist, 2011,16(11):1535-1546.
[9] Dawood S, Broglio K, Buzdar AU , et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review[J]. J Clin Oncol, 2010,28(1):92-98.
[10] Slamon DJ, Leyland-Jones B, Shak S , et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001,344(11):783-792.
[11] Burstein HJ, Keshaviah A, Baron AD , et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study[J]. Cancer, 2007,110(5):965-972.
[12] Robert N, Leyland-Jones B, Asmar L , et al. Randomized phase Ⅲ study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpres-sing metastatic breast cancer[J]. J Clin Oncol, 2006,24(18):2786-2792.
[13] Geyer CE, Forster J, Lindquist D , et al. Lapatinib plus capeci-tabine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2006,355(26):2733-2743.
[14] Cameron D, Casey M, Oliva C , et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase Ⅲ randomized trial[J]. Oncologist, 2010,15(9):924-934.
[15] Xu BH, Jiang ZF, Chua D , et al. Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients[J]. Chin J Cancer, 2011,30(5):327-335.
[16] Baselga J, Cortés J, Kim SB , Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. N Engl J Med, 2012,366(2):109-119.
[17] Verma S, Miles D, Gianni L , et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2012,367(19):1783-1791.
[18] Leyland-Jones B . Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases[J]. J Clin Oncol, 2009,27(31):5278-5286.
[19] Ramakrishna N, Temin S, Chandarlapaty S , et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2014,32(19):2100-2108.
[20] Ramakrishna N, Temin S, Chandarlapaty S , et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO clinical practice guideline update[J]. J Clin Oncol, 2018,36(27):2804-2807.
[21] Bachelot T, Romieu G, Campone M , et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study[J]. Lancet Oncol, 2013,14(1):64-71.
[22] Montemurro F, Ellis P, Delaloge S, et al. Safety and efficacy of trastuzumab emtansine(>T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study[J].Cancer Res, 2017, 77(4 Suppl):P1-12-10.
[1] 田佳宜,张霞,程功,刘庆红,王世阳,何菁. 系统性红斑狼疮患者血清白细胞介素-2受体α水平及其临床意义[J]. 北京大学学报（医学版）, 2021, 53(6): 1083-1087.
[2] 廖栩鹤,王荣福,刘萌,陈雪祺,熊焰,农琳,殷雷,张炳晔,杜毓菁. 18F-FDG PET/CT半定量参数、表皮生长因子受体和间变淋巴瘤激酶基因突变对肺腺癌患者预后评估的价值[J]. 北京大学学报（医学版）, 2021, 53(2): 246-254.
[3] 张晓鹏,张维宇,霍飞,胡浩,王起,许克新. 原发性女性膀胱出口梗阻的手术疗效随访及其发病机制[J]. 北京大学学报（医学版）, 2019, 51(6): 1052-1055.
[4] 梁学军,宫丽颖,周菲,周德敏,祝静静. 非天然氨基酸定点偶联抗人类表皮生长因子受体2-抗体偶联药物的药理学活性[J]. 北京大学学报（医学版）, 2019, 51(5): 797-804.
[5] 姚心韵,高晓敏,邹晓英,岳林. 胞内转运对根尖牙乳头干细胞表面CXC趋化因子受体4表达的影响[J]. 北京大学学报（医学版）, 2019, 51(5): 893-899.
[6] 丛馨,闵赛南,吴立玲,蔡志刚,俞光岩. 激活毒蕈碱乙酰胆碱受体调控下颌下腺分泌的机制研究[J]. 北京大学学报（医学版）, 2019, 51(3): 390-396.
[7] 张婧,陈洁,关贵文,张婷,鲁凤民,陈香梅. 肝细胞癌中趋化因子CXCL10及其受体CXCR3的表达及临床意义分析[J]. 北京大学学报（医学版）, 2019, 51(3): 402-408.
[8] 胥佳佳,王燕,孙贺,贾汝琳,张学武,孟洋,任丽丽,孙晓麟. 可溶性白细胞介素2受体α链的检测与类风湿关节炎疾病活动性评估[J]. 北京大学学报（医学版）, 2018, 50(6): 975-980.
[9] 王小慧，张岩，刘林枝，尚晨光. 二甲双胍与脂联素对子宫内膜癌细胞增殖的作用[J]. 北京大学学报(医学版), 2018, 50(5): 767-773.
[10] 周建华，王地，王焕瑞，侯晓利，郁卫东，许克新，胡浩. γδT细胞对膀胱癌细胞的细胞毒活性及MICA/B蛋白在膀胱癌中的表达[J]. 北京大学学报(医学版), 2018, 50(4): 595-601.
[11] 张晓东，刘德若. 肺腺癌新分类与表皮生长因子受体基因突变之间的关系[J]. 北京大学学报(医学版), 2018, 50(4): 640-644.
[12] 朱燕，石永进，赵玉亮，朱平. 拓扑异构酶抑制剂通过ATM/ATR和NF-κB途径上调乳腺癌细胞MICA/B 的表达[J]. 北京大学学报(医学版), 2018, 50(2): 318-325.
[13] 康磊，霍焱，王荣福，张春丽，闫平，徐小洁. MicroRNA-155靶向的放射性标记探针对乳腺癌小鼠模型的活体显像[J]. 北京大学学报(医学版), 2018, 50(2): 326-330.
[14] 刘凯宁，孟焕新，侯建霞. 维生素D受体FokⅠ多态性对牙周组织细胞CYP24A1表达的影响[J]. 北京大学学报(医学版), 2018, 50(1): 13-19.
[15] 朱云艳，李倩，张怡美，周彦恒. MAPK和AKT磷酸化下调参与Toll样受体抑制的人牙周膜干细胞的成骨分化[J]. 北京大学学报(医学版), 2018, 50(1): 33-41.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 张三. 中文标题测试[J]. 北京大学学报（医学版）, 2010, 42(1): 1 -10 .
[2] 赵磊, 王天龙 . 右心室舒张末期容量监测用于肝移植术中容量管理的临床研究[J]. 北京大学学报（医学版）, 2009, 41(2): 188 -191 .
[3] 万有, , 韩济生, John E. Pintar. 孤啡肽基因敲除小鼠电针镇痛作用增强[J]. 北京大学学报（医学版）, 2009, 41(3): 376 -379 .
[4] 张燕, 韩志慧, 钟延丰, 王盛兰, 李玲玲, 郑丹枫. 骨骼肌活组织检查病理诊断技术的改进及应用[J]. 北京大学学报（医学版）, 2009, 41(4): 459 -462 .
[5] 赵奇, 薛世华, 刘志勇, 吴凌云. 同向施压测定自酸蚀与全酸蚀粘接系统粘接强度[J]. 北京大学学报（医学版）, 2010, 42(1): 82 -84 .
[6] 林红, 王玉凤, 吴野平. 学校生活技能教育对小学三年级学生行为问题影响的对照研究[J]. 北京大学学报（医学版）, 2007, 39(3): 319 -322 .
[7] 丰雷, 程嘉, 王玉凤. 注意缺陷多动障碍儿童的运动协调功能[J]. 北京大学学报（医学版）, 2007, 39(3): 333 -336 .
[8] 李岳玲, 钱秋瑾, 王玉凤. 儿童注意缺陷多动障碍成人期预后及其预测因素[J]. 北京大学学报（医学版）, 2007, 39(3): 337 -340 .
[9] . 书讯[J]. 北京大学学报（医学版）, 2007, 39(3): 225 -328 .
[10] 牟向东, 王广发, 刁小莉, 阙呈立. 肺黏膜相关淋巴组织型边缘区B细胞淋巴瘤一例[J]. 北京大学学报（医学版）, 2007, 39(4): 346 -350 .
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部